Investors / ExSight Ventures
ExSight Ventures
Venture capital
ExSight Ventures is a life sciences venture capital firm that invests in early-stage ophthalmic diagnostic and treatment solutions. Its team of retinal surgeons invests in biotechnology, medical devices, pharmaceuticals, and software with ophthalmic applications.
Invests inHealthcare & Biotech
In its own wordsophthalmologylife sciencesbiotechnologymedical devicespharmaceuticalshealthcare software
Your fit with ExSight Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsExSight Ventures lists 13 checked portfolio companies on its own site and is named in 2 funding rounds, 2 of them as lead. Its most frequent entry is Seed, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in United States. It invests most often alongside Bios Partners, Accelerate Blue Fund and Ascension.
Counts come from funding rounds that name ExSight Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not ExSight Ventures' whole history. Rounds on record name 2 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 100% |
| Series A | 0% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 2 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 100th | 100% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Bios Partners | 2 |
| Accelerate Blue Fund | 1 |
| Ascension | 1 |
| Berkeley Catalyst Fund | 1 |
| Clarendon Fund Managers | 1 |
| Correlation Ventures | 1 |
| First Spark Ventures | 1 |
| Hatteras Venture Partners | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1292%
- No longer answers00%
- Points to another company18%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare ExSight Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with ExSight Ventures| Date | Company | Stage |
|---|---|---|
| 6 Nov 2025 | Seed Led | |
| 16 Sept 2025 | Seed Led |
Round details for ExSight Ventures
Amounts, full round histories and every co-investor in ExSight Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
| Portfolio page | ||||
| DefEYE, Inc. develops and provides products for ocular surface and surgical care. | Healthcare & Biotech | Nov 2025Seed | Funding round | |
| Portfolio page | ||||
| Elios Vision distributes and manufactures products for glaucoma treatment. | Healthcare & Biotech | Portfolio page | ||
| Horizon Surgical Systems has developed a surgical platform designed to bring new levels of precision, consistency, and access to cataract surgery. | Healthcare & Biotech | Portfolio page | ||
| LensGen is an ophthalmic medical device company that is developing a curvature changing fluid lens to avoid the need for reading glasses | Healthcare & Biotech | Portfolio page | ||
| Novai is a UK Medtech company combatting blindness and disability by pioneering early detection and intervention for eye and brain diseases using DARC technology | Healthcare & Biotech | Portfolio page | ||
| ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions | Healthcare & Biotech | Portfolio page | ||
| Re-Vana develops and delivers biodegradable ocular drug delivery systems for patients with sight-threatening diseases. | Healthcare & Biotech | Portfolio page | ||
| RevOpsis is focused on solving blindness with a vision for the rapid discovery and development of novel therapies using their modular RevMod Platform. | Healthcare & Biotech | Sept 2025Seed | Funding round | |
| Trefoil develops therapies for corneal diseases based on the regenerative properties of corneal cells. | Healthcare & Biotech | Portfolio page | ||
| Valitor develops ophthalmic medicines using its multivalent biopolymer technology to improve patient outcomes in ophthalmology and vision-threatening diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- exsightventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Sept 2025
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get ExSight Ventures' profile as data
Pull ExSight Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/exsightventures.com
# also
GET /v1/firms/exsightventures.com/portfolio
GET /v1/firms/exsightventures.com/coinvestors
GET /v1/firms/exsightventures.com/news